BioCentury
ARTICLE | Clinical News

Merck CMV prophylaxis headed for U.S., EU submissions

February 28, 2017 12:12 AM UTC

Merck & Co. Inc. (NYSE:MRK) said it will submit applications in the U.S. and EU this year for letermovir (MK-8228) to prevent cytomegalovirus (CMV) infection in CMV-seropositive recipients of an allogeneic hematopoietic stem cell transplantation (HSCT).

The announcement coincided with Merck’s presentation of data from a Phase III trial of letermovir at the BMT Tandem Meetings in Orlando. In October, the pharma reported that letermovir met the primary endpoint...